---
title: "Akero Therapeutics (AKRO.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AKRO.US.md"
symbol: "AKRO.US"
name: "Akero Therapeutics"
industry: "Biotechnology"
datetime: "2026-05-21T10:21:48.922Z"
locales:
  - [en](https://longbridge.com/en/quote/AKRO.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AKRO.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AKRO.US.md)
---

# Akero Therapeutics (AKRO.US)

## Company Overview

Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -15.36 | 507 | - | - | - |
| PB | 4.70 | 296 | 4.70 | 4.67 | 3.73 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-11-13T05:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 14% |
| Hold | 6 | 86% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 54.65 |
| Highest Target | 58.00 |
| Lowest Target | 54.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AKRO.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AKRO.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AKRO.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AKRO.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**